AGIO Agios Pharmaceuticals, Inc.

42

Healthcare [ 3/11 ] | Biotechnology [ 31/156 ]

US | NASDAQ | Stock

Price
$23.12
Increased by +0.02%
Dollar Volume
14.54 M
ADR%
4.55
Earnings Report Date (estimate)
May 3, 23 (-1.72)
Market Cap.
1.28 B
Shares Float
51.54 M
Shares Outstanding
55.29 M
Beta
0.96
Price / Earnings
-5.60
BPR
60.76
20D Range
21.12 27.20
50D Range
21.12 31.56
200D Range
16.75 34.76
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -1.49
Increased by +4.49%
 -1.76
Increased by +8.72%
Aug 4, 22 -1.68
Decreased by -19.15%
 -1.75
Increased by +2.29%
May 5, 22 -1.74
Decreased by -106.46%
 -1.81
Increased by +2.14%
Feb 24, 22 -1.74
Decreased by -23.40%
 -1.69
Decreased by -1.75%
Nov 3, 21 -1.56
Decreased by -9.09%
 -1.59
Increased by +1.19%
Jul 29, 21 -1.41
Decreased by -7.63%
 -1.39
Decreased by -1.04%
Apr 29, 21 26.95
Increased by +4.67 K%
 -1.32
Increased by +1.62 K%
Feb 25, 21 -1.41
Increased by +11.88%
 -1.33
Decreased by -4.52%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 3.52 M
Increased by +N/A%
 -81.75 M
Increased by +7.91%
Decreased by -2.33 K%
Decreased by N/A%
Jun 30, 22 5.58 M
Increased by +N/A%
 -91.81 M
Decreased by -6.48%
Decreased by -1.64 K%
Decreased by N/A%
Mar 31, 22 832.00 K
Increased by +N/A%
 -94.77 M
Decreased by -105.06%
Decreased by -11.39 K%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by -100.00%
 -94.63 M
Increased by +3.10%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
 -88.77 M
Increased by +10.32%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
 -86.22 M
Increased by +4.71%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by -100.00%
 1.87 B
Increased by +4.76 K%
Increased by +N/A%
Increased by +N/A%
Dec 31, 20 44.05 M
Increased by +24.28%
 -97.66 M
Increased by +4.59%
Decreased by -221.72%
Increased by +23.23%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.